HPV-related research

Human Papillomavirus (HPV) is a very common group of viruses that, in the most severe cases, can lead to cancer in the cervix, as well as other organs. The Cancer Registry is involved in several projects that aim to increase knowledge about HPV.

The Cancer Registry of Norway has carried out research on human papillomavirus (HPV) and cancer, since the 1990s. Our research includes the incidence, prevention, natural course and development of cancer, as well as evaluation of the effect and safety of the HPV vaccine Gardasil in Norway and the Nordic countries. Projects that promote the idea of personalized mass screening have been initiated to optimize cancer screening.


Several HPV vaccines have been developed, including Cervarix for high-risk HPV16 and 18, and Gardasil 9 for high-risk HPV16, 18, 31, 33, 45, 52 and 58 as well as low-risk HPV6 and 11 that can cause genital warts. All HPV vaccines contain protection against HPV16 and 18, which are the most serious high-risk types. These two types of viruses cause around 70 percent of cervical cancer cases. All HPV vaccines are preventive and therefore most effective if given before exposure to HPV, i.e. before sexual debut.


Some of our ongoing research projects:

HPV-sequencing for biomarkers

Fight HPV and cervical cancer

LTFU: Long-term follow up of subjects participating in the clinical trials of the HPV-vaccine

Equalscreen - increased attendance and reduced inequity in cervical cancer screening

Personalised cervical cancer screening

Biomarkers for HPV-related cancers